source
- Scholar Rock removes Novo Nordisk's Catalent plant from FDA filing for SMA drug apitegromabScholar Rock announced it will no longer list Novo Nordisk’s legacy Catalent facility as a contract manufacturer in its FDA resubmission for apitegromab, its spinal muscular atrophy (SMA) candidate…
- MoonLake reports all endpoints met in phase 3 trial of sonelokimab for psoriatic arthritisMoonLake Immunotherapeutics said its lead nanobody sonelokimab achieved positive topline results in a phase 3 study of patients with psoriatic arthritis. At week 16, 42.1% of participants reached…